



*AMENDMENTS TO THE CLAIMS*

This listing of claims replaces all prior versions, and listings, of claims in the application.


1. (Original) A therapeutic agent for schizophrenia, which comprises, as an active ingredient, a compound of the formula (I)




wherein  $\text{R}^1$  is a  $\text{C}_2$ - $\text{C}_6$  alkyl group or the formula (II)




wherein  $\text{R}^2$  is a hydrogen atom or an acetyl group and  $\text{R}^3$  is a  $\text{C}_1$ - $\text{C}_6$  alkyl group, a cycloalkyl group or




wherein  $\text{R}^4$  and  $\text{R}^5$  are each independently a hydrogen atom or a  $\text{C}_1$ - $\text{C}_6$  alkyl group, and in




of the formula (II),  $\text{R}^2$  and  $\text{R}^3$  may be linked to each other to form




wherein  $R^6$  is a hydrogen atom or a  $C_1$ - $C_6$  alkyl group;




wherein  $R^7$  and  $R^8$  are each independently a hydrogen atom or a  $C_1$ - $C_4$  alkyl group,



wherein  $R^9$  and  $R^{10}$  are each independently a hydrogen atom or a  $C_1$ - $C_4$  alkyl group,




wherein  $R^{11}$  is a hydrogen atom or a  $C_1$ - $C_4$  alkyl group; and




wherein  $R^{12}$  and  $R^{13}$  are each independently a  $C_1$ - $C_4$  alkyl group or may be linked to each other to form




wherein n is an integer of 2 to 6, or



wherein m is an integer of 2 or 3,





wherein R<sup>14</sup> is a hydrogen atom or a C<sub>1</sub>-C<sub>4</sub> alkyl group,



wherein R<sup>15</sup> is a hydrogen atom or an aralkyl group, or




provided that when




and R<sup>7</sup> should not be a hydrogen atom, an enantiomer thereof, an acid addition salt thereof, or a hydrate or solvate thereof.


2. (Currently Amended) The therapeutic agent of claim 1, wherein the compound of the formula (I) is a compound of the formula (Ia)




wherein  $R^{1'}$  is a  $C_2$ - $C_6$  alkyl group or the formula (II)',




wherein  $R^2$  is a hydrogen atom or an acetyl group, and  $R^{3'}$  is a  $C_1$ - $C_6$  alkyl group or



wherein  $R^4$  and  $R^5$  are each independently a hydrogen atom or a  $C_1$ - $C_6$  alkyl group, and in




of the formula (II)',  $R^2$  and  $R^{3'}$  may be linked to each other to form



wherein  $R^6$  is a hydrogen atom or a  $C_1$ - $C_6$  alkyl group;


$R^{9'}$  and  $R^{10'}$  are each independently a  $C_1$ - $C_4$  alkyl group; and



wherein  $R^{15'}$  is an alkyl group, or




3. (Original) The therapeutic agent of claim 1, wherein the compound of the formula (I) is a 4-acylamino-5,6,7,8-tetrahydrofuro[2,3-b]quinoline derivative of the formula (Ib)




(I b)

wherein  $R^{1''}$  is a  $C_2$ - $C_6$  alkyl group,



or



wherein  $R^6$  is a hydrogen atom or a  $C_1$ - $C_6$  alkyl group; and

$R^9$  and  $R^{10}$  are each independently a hydrogen atom or a  $C_1$ - $C_4$  alkyl group.

4. (Original) The therapeutic agent of claim 1, wherein the compound of the formula (I) is 2-(2-oxopyrrolidin-1-yl)-N-(2,3-dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)acetamide.

5. (Previously Presented) The therapeutic agent of claim 1, wherein the condition of schizophrenia is a negative symptom or a cognitive disorder.

6. (Previously Presented) The therapeutic agent of claim 2, wherein the condition of schizophrenia is a negative symptom or a cognitive disorder.

7. (Previously Presented) The therapeutic agent of claim 3, wherein the condition of schizophrenia is a negative symptom or a cognitive disorder.

8. (Previously Presented) The therapeutic agent of claim 4, wherein the condition of schizophrenia is a negative symptom or a cognitive disorder.